Free tool
FAERS Monitor: Atzumi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217901 or its brand name (Atzumi, Dihydroergotamine Mesylate). Reports on generic versions are filed under their own applications.
Reports
829
Serious
652
79% of reports
Hospitalization
139
Death reported
21
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective387
- off label use359
- hyperhidrosis356
- nightmare339
- sedation339
- nausea338
- product use in unapproved indication293
- nephrolithiasis252
- migraine79
- treatment failure57
- dyspnoea52
- abdominal pain47
- diarrhoea47
- cough46
- weight decreased43
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 16 |
| 2006 | 24 |
| 2007 | 24 |
| 2008 | 20 |
| 2009 | 15 |
| 2010 | 18 |
| 2011 | 26 |
| 2012 | 26 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 9 |
| 2017 | 18 |
| 2018 | 14 |
| 2019 | 26 |
| 2020 | 18 |
| 2021 | 64 |
| 2022 | 70 |
| 2023 | 50 |
| 2024 | 125 |
| 2025 | 84 |
| 2026 | 159 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,330 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sedationSignal | 339 | 332.7 | 306.3 | 110,469 |
| nightmareSignal | 339 | 251.0 | 231.1 | 83,486 |
| nephrolithiasisSignal | 252 | 140.2 | 126.4 | 34,564 |
| hyperhidrosisSignal | 356 | 70.3 | 65.0 | 24,337 |
| product use in unapproved indicationSignal | 293 | 30.0 | 27.4 | 8,281 |
| migraineSignal | 79 | 21.0 | 17.0 | 1,491 |
| treatment failureSignal | 57 | 17.5 | 13.6 | 871 |
| nauseaSignal | 338 | 10.8 | 10.0 | 3,125 |
| off label useSignal | 359 | 10.4 | 9.6 | 3,174 |
| drug ineffectiveSignal | 387 | 7.5 | 6.9 | 2,299 |
| abdominal painSignal | 47 | 5.1 | 3.9 | 154 |
| coughSignal | 46 | 4.2 | 3.1 | 109 |
| weight decreasedSignal | 43 | 3.9 | 2.9 | 91 |
| dyspnoeaSignal | 52 | 2.3 | 1.8 | 39 |
| diarrhoea | 47 | 1.8 | 1.4 | 18 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.